Journal of Experimental & Clinical Cancer Research 2009, 28:89 http://www.jeccr.com/content/28/1/89 development of final manuscript. SL: background litera- ture search, data analysis. WX: data analysis, background literature search. XLW: research instruction, background literature search. WHZ: research instruction, development of final manuscript. References 1. Spiro SG, Silvestri GA: One hundred years of lung cancer. Am J Respir Crit Care Med 2005, 172:523-529. 2. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: a prospective study. Science 1998, 279:563-566. 3. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentra- tions of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396. 4. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999, 91:620-625. 5. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-con- trol analysis. J Natl Cancer Inst 1999, 91:151-156. 6. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000, 92:1472-1489. 7. Giovannucci E: Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001, 131(11 Suppl):S3109-S3120. 8. Clemmons DR: Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007, 6:821-833. 9. Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY: Antimetastatic activity of insulin- like growth factor binding protein-3 in lung cancer is medi- ated by insulin-like growth factor-independent urokinase- type plasminogen activator inhibition. Mol Cancer Ther 2006, 5:2685-2695. 10. Hofmann F, Garcia-Echeverria C: Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005, 10:1041-1047. 11. Tao Y, Pinzi V, Bourhis J, Deutsch E: Mechanisms of disease: sig- naling of the insulin-like growth factor 1 receptor pathway– therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007, 4:591-602. 12. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY: Cor- relation between insulin-like growth factor-binding protein- 3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002, 8:3669-3675. 13. Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY: Clinical significance of insulin-like growth factor- binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 2002, 8:3796-3802. 14. Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Haley NJ, Shore RE, Riboli E, Rinaldi S, Kaaks R: A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 2001, 92:888-892. 15. London SJ, Yuan JM, Travlos GS, Gao YT, Wilson RE, Ross RK, Yu MC: Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 2002, 94:749-754. 16. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M: Serum insulin-like growth factor (IGF) and IGF-binding pro- tein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev 2002, 11:1413-1418. 17. Wakai K, Ito Y, Suzuki K, Tamakoshi A, Seki N, Ando M, Ozasa K, Watanabe Y, Kondo T, Nishino Y, Ohno Y: Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Jpn J Cancer Res 2002, 93:1279-1286. 18. Ahn J, Weinstein SJ, Snyder K, Pollak MN, Virtamo J, Albanes D: No association between serum insulin-like growth factor (IGF)- I, IGF-binding protein-3, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15:2010-2012. 19. Morris JK, George LM, Wu T, Wald NJ: Insulin-like growth fac- tors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiologi- cal studies. Br J Cancer 2006, 95:112-117. 20. Cochran WG: The combination of estimates from different experiments. Biometrics 1954, 10:101-129. 21. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748. 22. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 23. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta- analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 24. Pollak MN: Endocrine effects of IGF-I on normal and trans- formed breast epithelial cells: potential relevance to strate- gies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998, 47:209-217. 25. Olivecrona H, Hilding A, Ekström C, Barle H, Nyberg B, Möller C, Delhanty PJ, Baxter RC, Angelin B, Ekström TJ, Tally M: Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans. J Clin Endo- crinol Metab 1999, 84:553-560. 26. Chin E, Zhou J, Dai J, Baxter RC, Bondy CA: Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex. Endocrinology 1994, 134:2498-2504. 27. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ, Hill DJ: Differ- ential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994, 79:1871-1876. Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp BioMedcentral Page 6 of 6 (page number not for citation purposes)